Perennial Investment Advisors LLC Buys 272 Shares of Pfizer Inc. (NYSE:PFE)

Perennial Investment Advisors LLC raised its stake in shares of Pfizer Inc. (NYSE:PFEGet Rating) by 1.8% in the 1st quarter, Holdings Channel reports. The firm owned 15,180 shares of the biopharmaceutical company’s stock after purchasing an additional 272 shares during the quarter. Perennial Investment Advisors LLC’s holdings in Pfizer were worth $788,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of PFE. Baltimore Washington Financial Advisors Inc. bought a new stake in shares of Pfizer during the 4th quarter valued at about $290,000. PYA Waltman Capital LLC bought a new position in shares of Pfizer during the 4th quarter worth approximately $31,000. Rinkey Investments bought a new position in shares of Pfizer during the 4th quarter worth approximately $32,000. Bivin & Associates Inc. bought a new position in shares of Pfizer during the 4th quarter worth approximately $37,000. Finally, Stuart Chaussee & Associates Inc. boosted its holdings in shares of Pfizer by 108.3% during the 1st quarter. Stuart Chaussee & Associates Inc. now owns 625 shares of the biopharmaceutical company’s stock worth $32,000 after buying an additional 325 shares in the last quarter. 66.50% of the stock is owned by institutional investors.

Insider Activity

In other news, EVP William R. Carapezzi, Jr. sold 32,908 shares of the stock in a transaction on Thursday, May 12th. The stock was sold at an average price of $50.00, for a total transaction of $1,645,400.00. Following the completion of the transaction, the executive vice president now owns 38,146 shares in the company, valued at approximately $1,907,300. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, SVP Jennifer B. Damico sold 4,218 shares of the stock in a transaction on Tuesday, June 7th. The stock was sold at an average price of $53.96, for a total transaction of $227,603.28. Following the completion of the transaction, the senior vice president now owns 10,846 shares in the company, valued at approximately $585,250.16. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP William R. Carapezzi, Jr. sold 32,908 shares of the stock in a transaction on Thursday, May 12th. The stock was sold at an average price of $50.00, for a total value of $1,645,400.00. Following the transaction, the executive vice president now owns 38,146 shares of the company’s stock, valued at approximately $1,907,300. The disclosure for this sale can be found here. Insiders sold a total of 41,126 shares of company stock valued at $2,075,003 in the last ninety days. 0.05% of the stock is currently owned by insiders.

Pfizer Stock Down 1.0 %

NYSE PFE traded down $0.49 on Friday, reaching $49.37. The company had a trading volume of 463,914 shares, compared to its average volume of 16,919,380. Pfizer Inc. has a 52-week low of $40.94 and a 52-week high of $61.71. The stock has a market capitalization of $277.01 billion, a P/E ratio of 9.77, a P/E/G ratio of 0.61 and a beta of 0.67. The company’s fifty day moving average is $51.18 and its 200 day moving average is $51.14. The company has a quick ratio of 1.13, a current ratio of 1.39 and a debt-to-equity ratio of 0.43.

Pfizer (NYSE:PFEGet Rating) last announced its earnings results on Thursday, July 28th. The biopharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.95 by $0.09. Pfizer had a return on equity of 44.38% and a net margin of 28.92%. The firm had revenue of $27.74 billion during the quarter, compared to analyst estimates of $26.20 billion. During the same period last year, the firm posted $1.07 EPS. The business’s revenue was up 46.8% compared to the same quarter last year. Sell-side analysts anticipate that Pfizer Inc. will post 6.54 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 6th. Stockholders of record on Wednesday, June 29th will be given a dividend of $0.40 per share. This represents a $1.60 annualized dividend and a dividend yield of 3.24%. The ex-dividend date is Thursday, July 28th. Pfizer’s dividend payout ratio is presently 31.31%.

Analysts Set New Price Targets

A number of research firms have issued reports on PFE. The Goldman Sachs Group set a $50.00 price target on Pfizer in a report on Friday, July 29th. Morgan Stanley cut their price target on Pfizer from $52.00 to $49.00 and set an “equal weight” rating on the stock in a report on Friday, July 8th. SVB Leerink cut their price target on Pfizer from $55.00 to $53.00 and set a “market perform” rating on the stock in a report on Friday, July 29th. Wells Fargo & Company cut their price target on Pfizer from $60.00 to $55.00 in a report on Wednesday, May 4th. Finally, Barclays upped their target price on Pfizer from $50.00 to $52.00 and gave the stock an “equal weight” rating in a research report on Monday. Nine investment analysts have rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $57.50.

About Pfizer

(Get Rating)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.

Further Reading

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFEGet Rating).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.